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Letters to the Editoris beneficial to the lungs of pigs under
conditions of CPB. Can that be extrap-
olated to man?
An important issue to be addressed
is whether lung ventilation/perfusion,
during conditions of CPB, promotes
gas exchange. We3 have performed
all valve procedures with the heart
beating, perfused simultaneously ante-
gradely and retrogradely with warm
blood, and with the lungs ventilated/
perfused during the cardiac procedure,
in an effort to decrease ischemia–
reperfusion injury. End-tidal carbon
dioxide (ETCO2), a measurement of
pulmonary blood flow and cardiac
output, was continuously monitored.
ETCO2 provides a noninvasive esti-
mate of cardiac output, through the
ratio of change in ETCO2 partial pres-
sure and CO2 elimination after a brief
period of partial rebreathing.4 Expired
CO2 is assessed by a noninvasive CO2
monitor that integrates the differential
CO2 Fick partial rebreathing tech-
nique.5 Preliminary work shows that
ETCO2 is an excellent indicator of
lung perfusion, but its clinical value re-
mains unclear. ETCO2 continued to be
present once CPB was initiated and
was unchanged throughout the opera-
tions. An example of one valve case
is shown in Figure 1. Perfusion/venti-
lation of the lungs did not interfere
with the operation.
Recently, we received institutional
review board approval for a prospec-
tive randomized clinical trial to evalu-
ate lung perfusion/ventilation during
CPB. Results will be forthcoming.
On the basis of initial experience by
Imura and associates2 in pigs and our
own experience with humans, in long
and complicated procedures, or in
patients with pre-existing pulmonary
diseases, lung perfusion/ventilation is
recommended. Potentially, lung injury
can be decreased in these patients.
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We thank Dr Macedo and col-
leagues for their interest in our study
on low-frequency ventilation during
cardiopulmonary bypass (CPB) that
was recently published in the Journal.1
They share our interest in lung injury
during cardiac surgery and how to pre-
vent it. We believe this is relevant to
current practice with an ever-increas-
ing population of high-risk patients.
The rationale beyond our interest in
lung injury is based on the simple
observation that in current clinical
practice, once CPB is instituted, the
patient’s lungs are disconnected from
the ventilator and left open to the air,
fully collapsed and poorly perfused
for the duration of CPB. Our report
showed significant ischemic damage
and atelectasis in the collapsed lungs
during and after CPB, and these were
improved by using low-frequency
ventilation during CPB.1 Althoughardiovascular Surgery c January 2009the underlying mechanisms are still
unclear, there have been reports sug-
gesting that ventilation during CPB
may reduce damage in the lungs.2
We have taken this forward and are
now about to start a large clinical trial
to assess low-frequency ventilation in
clinical practice.
The issue of pulmonary perfusion
during cardiac surgery is an interesting
one. Current practice is based on the as-
sumption that bronchial blood supply is
sufficient for lung protection during
CPB.3 Yet, during cardiac surgery the
bronchial circulation (only 1%–2% of
the cardiac output) is jeopardized by
CPB and surgery-related factors, includ-
ing lungcollapse, internal thoracic artery
harvesting, aortic manipulation, hypo-
thermia, and loss of pulsatile flow. Sche-
lensak and colleagues4 showed that
there is significant decrease in bronchial
arterial flow during the initial phase of
total CPB and that flow remains low un-
til the end of CPB, returning to normal
by 60 minutes of reperfusion.
This highlights the importance that
pulmonary circulation may have for
alveolar oxygenation, which is also
supported by the observation that dur-
ing lung transplantation surgery the
bronchial arteries rarely are recon-
nected without obvious lung ischemia.
Pulmonary artery perfusion is an
obvious potential intervention to pre-
vent lung ischemia. Along with Dr
Macedo and colleagues, we are cur-
rently focusing on this in ongoing ex-
perimental research.
Others have suggested that ventila-
tion during CPB can reduce lung
injury.4,5 In our view, the safety, effi-
cacy, and surgical practicality of pulmo-
nary perfusion during CPB remains to
be proven beyond any doubt before
establishing it in clinical practice. Also,
there is still a lot of research to undertake
to ascertain themechanistic insights, the
dominance of ventilation versus perfu-
sion or vice versa as a protective inter-
vention, and the best route or mode of
delivery of pulmonary perfusion.
Letters to the EditorWith regard to the possible resistance
by surgeons to adopt these interven-
tions, we think the availability of com-
pelling evidence in support of these
interventions to prevent lung injury
will eliminate any practical concerns.
Dr Macedo and colleagues refer to
a trial that will assess the effect of lung
perfusion/ventilation during CPB. We
look forward to their results, which
will hopefully add further knowledge
to face the continued ch allenge of
lung injury during cardiac surgery.
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FOR MITRALVALVE
REPLACEMENT: MAKING
A SIMPLE PROCEDURE
COMPLEX?
To the Editor:
I read with interest the article by
Kumar and colleagues1 about the useThe Journalof pulmonary autografts for mitral
valve replacement. I agree with the au-
thors that cardiac surgeons working in
Third World countries are faced with
a major problem in the management
of large numbers of patients with val-
vular disease. Most of those patients
are of low socioeconomic and educa-
tional class, living in remote villages
and mountains. There is no family
practice or general practitioner system
to provide early diagnosis and referral,
postoperative follow-up, and anticoa-
gulation control. Patients usually pres-
ent late with advanced disease that
makes repair impossible. The magni-
tude of the problem is escalated in chil-
dren and women of childbearing age
because we have no ideal valve
substitute.
The pulmonary autograft concept is
attractive but still has its drawbacks
and complications. The procedure is
complex and technically demanding,
requiring at least double the usual
crossclamp and bypass times. The
procedure is not free of charge be-
cause there is a price for the homo-
grafts or preparation of the
autografts, plus the added cost of
complications. The mortality of ap-
proximately 15% reported by the au-
thors is still high compared with
single mitral valve replacement. Kab-
bani and colleagues2 reported 5%
early mortality and 6% late mortality,
but as they stated, it is ‘‘clearly re-
lated to the procedure,’’ which entails
higher overall mortality. The issue of
converting a single-valve into a dou-
ble-valve disease is irritating because
we have to expect long-term sequelae
of pulmonary and mitral valve fail-
ures. The main concern with pulmo-
nary autografts or homografts is
early calcification. The removal of
calcified grafts, as experienced in aor-
tic homografts, is usually disastrous
and has a high complication rate, in-
cluding left ventricular rupture. The
same complications are associated
with the use of aortic or mitral homo-
grafts for mitral valve replacement.
All of these autografts and homo-of Thoracic and Cardiovascular Surgegrafts have to compete with the stan-
dard stented bioprostheses, which are
improving and technically easier to
insert, and require no anticoagulation.
At the present time, bioprosthetic
valves remain the standard in these
patients, and manufacturers have
shown us better preservation and lon-
ger durability.3
Khaled E. Al-Ebrahim, FRCSC
Department of Cardiothoracic
Surgery
King Abduaziz University
Jeddah, Saudi Arabia
References
1. Kumar AS, Talwar S, Gupta A.Mitral valve replace-
ment with the pulmonary autograft: midterm results.
J Thorac Cardiovasc Surg. 2009;138:359-64.
2. Kabbani SS, Jamil H, Hammoud A, Hatab JA,
Nabhani F, Hariri R, et al. The mitral pulmonary au-
tograft: assessment at midterm. Ann Thorac Surg.
2004;78:60-5.
3. Totaro P, Degno N, Zaidi A, Youhana A, Argano V.
Carpentier Edwards Perimount Magna bioprosthe-
ses: a stented valve with stentless performance? J
Thorac Cardiovasc Surg. 2005;130:1668-74.
doi:10.1016/j.jtcvs.2009.08.049Reply to the Editor:
We are thankful to Dr Khaled E. Al-
Ebrahim for his comments and cri-
tique. These were the same arguments
raised when the Ross procedure for
aortic valve replacement was first
reported by Donald Ross in 1967.
The patients undergoing operation
are young and clearly unsuitable for
tissue valves. The surgery is indeed
complex but provides superior hemo-
dynamic results with a higher valve
area. In addition, these patients only
require an echocardiogram at yearly
intervals, receive no medication 1
year after surgery, and do not require
blood tests. The most important
advantage is that it is a living valve,
and we now have more than a 15-
year follow-up of our own results for
the Ross (aortic valve replacement)
procedure. There has been no reopera-
tion in the adults with a pulmonary
homograft.
We believe these early results will
translate into superior outcomes inry c Volume 139, Number 1 237
